Literature DB >> 7963545

Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy.

E Gussoni1, G K Pavlath, R G Miller, M A Panzara, M Powell, H M Blau, L Steinman.   

Abstract

Mononuclear cells infiltrate degenerating muscles of Duchenne muscular dystrophy (DMD) patients. Using a quantitative PCR, we first characterized the T cells infiltrating muscle biopsies from six DMD patients. High levels of TCR V beta 2 transcripts were observed in DMD muscle tissue. TCR V beta 2 transcripts from seven DMD patients and five controls were sequenced, and the VDJ junctional region analyzed in 166 clones. One specific amino acid motif, RVSG, was found in the third complementary determining region (CDR3) of TCR V beta 2 chains in samples from five DMD patients, but not in controls. A specific immune reaction at the site of tissue degeneration may play an important role in the pathogenesis of DMD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963545

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Dystrophin immunity in Duchenne's muscular dystrophy.

Authors:  Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Autoimmunity, recessive diseases, and gene replacement therapy.

Authors:  James M Wilson
Journal:  Mol Ther       Date:  2010-12       Impact factor: 11.454

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 4.  Shared signaling systems in myeloid cell-mediated muscle regeneration.

Authors:  James G Tidball; Kenneth Dorshkind; Michelle Wehling-Henricks
Journal:  Development       Date:  2014-03       Impact factor: 6.868

Review 5.  Tissue Tregs.

Authors:  Marisella Panduro; Christophe Benoist; Diane Mathis
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

6.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.

Authors:  Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

Review 7.  Regulatory interactions between muscle and the immune system during muscle regeneration.

Authors:  James G Tidball; S Armando Villalta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-10       Impact factor: 3.619

8.  Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity.

Authors:  M J Spencer; C M Walsh; K A Dorshkind; E M Rodriguez; J G Tidball
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 9.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

10.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Authors:  Sylvia A Vetrone; Encarnacion Montecino-Rodriguez; Elena Kudryashova; Irina Kramerova; Eric P Hoffman; Scot D Liu; M Carrie Miceli; Melissa J Spencer
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.